相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
Vittorio Rosti et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years
Francesca Palandri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gordon H. Guyatt et al.
CHEST (2012)
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
H. Reikvam et al.
LEUKEMIA (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
How to manage thrombosis in myeloproliferative neoplasms
Tiziano Barbui
CURRENT OPINION IN ONCOLOGY (2011)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
Tiziano Barbui et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms
J. Hoekstra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Heparin-Induced Thrombocytopenia in Patients with Philadelphia-Negative Myeloproliferative Disorders and Unusual Splanchnic or Cerebral Vein Thrombosis
Maria L. Randi et al.
ACTA HAEMATOLOGICA (2010)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Thrombohemorrhagic complications of myeloproliferative disorders
Emmanouil Papadakis et al.
BLOOD REVIEWS (2010)
Myeloproliferative Disorders and the Hyperviscosity Syndrome
Bruce D. Adams et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms
Giuseppe Cella et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms
Jerome Duchemin et al.
THROMBOSIS RESEARCH (2010)
JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
Alessandra Carobbio et al.
EXPERIMENTAL HEMATOLOGY (2009)
JAK2V617F Mutation-positive Childhood Essential Thrombocythemia Associated With Cerebral Venous Sinus Thrombosis
Hidemitsu Kurosawa et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia
Issa J. Dahabreh et al.
LEUKEMIA RESEARCH (2009)
Heparin-induced thrombocytopenia in myeloproliferative disorders: A rare or under-diagnosed complication?
Galia Spectre et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
Marina Marchetti et al.
BLOOD (2008)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia:: a retrospective survey
Marco Ruggeri et al.
BLOOD (2008)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Hemorrhagic complications of anticoagulant and thrombolytic treatment
Sam Schulman et al.
CHEST (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Prevention of thrombosis in polycythemia vera and essential thrombocythemia
Raffaele Landolfi et al.
HAEMATOLOGICA (2008)
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation
R. Landolfi et al.
LEUKEMIA (2008)
Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with Essential Thrombocythemia
Franca Radaelli et al.
HEMATOLOGICAL ONCOLOGY (2007)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin α5 chain and Lu/BCAM
Marie-Paule Wautier et al.
BLOOD (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F
Akyalew Tefferi et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
Anna Falanga et al.
EXPERIMENTAL HEMATOLOGY (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Alessandra Carobbio et al.
BLOOD (2007)
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
D. Colaizzo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis
S. Regina et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules (vol 35, jpg 702, 2007)
A. Falanga et al.
EXPERIMENTAL HEMATOLOGY (2007)
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Massimo Primignani et al.
HEPATOLOGY (2006)
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D. Hull et al.
AMERICAN JOURNAL OF MEDICINE (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis
Marjorie Boissinot et al.
BLOOD (2006)
Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?
Ayalew Tefferi et al.
BLOOD (2006)
The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera
Jan J. Michiels et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome
Raj K. Patel et al.
GASTROENTEROLOGY (2006)
Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
P Johansson
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders:: Diagnosis and management
JB Brière
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
A Tefferi et al.
CANCER (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils
A Falanga et al.
SEMINARS IN HEMATOLOGY (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis
MF McMullin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
C Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
A Falanga et al.
EXPERIMENTAL HEMATOLOGY (2005)
Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis
Y Chait et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia
MA Elliott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera
M Karakantza et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Factor V Leiden mutation carriership and venous thromboembolism in Polycythemia Vera and Essential Thrombocythemia
M Ruggeri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2002)
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area
MK Jensen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
MK Jensen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
